Answers are grounded in this paper and cite their sources.
Endogenous long-acting proteins, particularly IgG-based affinity-controlled release, prolonged the serum half-life as well as significantly enhanced the antitumor effect of TRAIL. IgBD-mediated endogenous IgG binding might be a novel approach for the affinity-controlled release of other protein drugs.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: